Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Sept. 14 — Sens. Amy J. Klobuchar (D-Minn.) and Chuck Grassley (R-Iowa) Sept. 9 reintroduced a bill (S. 2019) that would make drug company pay-for-delay settlements presumptively illegal.
The Preserve Access to Affordable Generics Act addresses the practice in which a patent-owning brand name drug manufacturer pays a generic maker to cease its patent validity challenge in court and stay out of the market until the patent expires or just before it expires.
“Pay-for-delay pharmaceutical deals force consumers to pay higher prices by keeping affordable alternatives to brand-name drugs off the market,” Klobuchar said. “Our legislation will help ensure people have access to the medications they need at a price they can afford by putting an end to these harmful agreements once and for all.”
The bill has been referred to the Senate Judiciary Committee for consideration.
The senators said in a press release that pay-for-delay agreements delay generic entry into the market an average of nearly 17 months longer than agreements without payments.
“Pay for delay deals keep drug costs artificially high for consumers and the taxpaying public,” Grassley said. “These agreements disrupt the current law that was put in place to speed generic drugs getting to the market. In addition, they force consumers to pay more for their medicines, and add an exorbitant burden to the deficit.”
Klobuchar and Grassley reintroduced similar legislation in 2013.
They also introduced the legislation (S. 27) in 2011. On July 21, 2011, the Senate Judiciary Committee approved the legislation, but it never made it to the full Senate for a vote.
On Sept. 10, Sen. Bernie Sanders (I-Vt.) introduced a wide-ranging prescription drug bill (S. 2023), which includes a ban on pay-for-delay settlements.
While the Generic Pharmaceutical Association didn't have any immediate response to the Klobuchar-Grassley bill Sept. 14, the group in 2013 sponsored a report finding that drug patent litigation settlements save consumers money, by bringing generics to market before a patent expires.
The question of whether pay-for-delay (also called reverse payment) settlements are illegal reached the U.S. Supreme Court. In a 2013 ruling, the high court said a “rule of reason” approach must be applied to determining whether reverse payment deals between branded and generic drug companies are anticompetitive but declined to hold that reverse payments are presumptively illegal.
The bill is at http://op.bna.com/hl.nsf/r?Open=bdmr-a2cncf.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)